Show simple item record

dc.contributor.authorStordal, Britta
dc.contributor.authorPavlakis, Nick
dc.contributor.authorDavey, Ross
dc.date.accessioned2009-02-24T00:58:39Z
dc.date.available2009-02-24T00:58:39Z
dc.date.issued2007
dc.identifier.citationStordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007 Dec;33(8):688-703.en
dc.identifier.urihttp://hdl.handle.net/2123/4068
dc.description.abstractWe undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance. Medline was searched for 1) cell models of acquired drug resistance reporting platinum and taxane sensitivities and 2) clinical trials of platinum or taxane salvage therapy in ovarian cancer. 137 models of acquired drug resistance were identified. 68.1% of cisplatin-resistant cells were sensitive to paclitaxel and 66.7% of paclitaxel-resistant cells were sensitive to cisplatin. A similar inverse pattern was observed for cisplatin vs docetaxel, carboplatin vs paclitaxel and carboplatin vs docetaxel. These associations were independent of cancer type, agents used to develop resistance and reported mechanisms of resistance. 65 eligible clinical trials of paclitaxel-based salvage after platinum therapy were identified. Studies of single agent paclitaxel in platinum-resistant ovarian cancer where patients had previously recieved paclitaxel had a pooled response rate of 35.3% n=232, compared to 22% in paclitaxel naïve patients n=1918 (p<0.01 Chi-squared). Suggesting that pre-treatment with paclitaxel may improve the response of salvage paclitaxel therapy. The response rate to paclitaxel/platinum combination regimens in platinum-sensitive ovarian cancer was 79.5% n=88 compared to 49.4% n=85 for paclitaxel combined with other agents (p<0.001 Chi-squared), suggesting a positive interaction between taxanes and platinum. Therefore the inverse relationship between platinum and taxanes resistance seen in cell models is mirrored in the clinical response to these agents in ovarian cancer. An understanding of the cellular and molecular mechanisms responsible would be valuable in predicting response to salvage chemotherapy and may identify new therapeutic targets.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsThe University of Sydney claims copyright ownership of all information stored on this site, unless expressly stated otherwise.en
dc.subjectCisplatinen
dc.subjectCarboplatinen
dc.subjectPaclitaxelen
dc.subjectDocetaxelen
dc.subjectResistanceen
dc.subjectSensitivityen
dc.subjectCross-Resistanceen
dc.subjectOvarian Canceren
dc.titleA systematic review of platinum and taxane resistance from bench to clinic: an inverse relationshipen
dc.typeArticleen
dc.contributor.departmentBill Walsh Cancer Research Laboratoriesen
dc.identifier.doihttp://dx.doi.org/10.1016/j.ctrv.2007.07.013


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record